Trial Profile
Prospective, Single Arm, Open-label, Multicenter, International Study to Assess the Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome During a 12-week Treatment Period Followed by an Extension Period of 24 Weeks
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Metyrapone (Primary)
- Indications Cushing syndrome
- Focus Registrational; Therapeutic Use
- Acronyms PROMPT
- Sponsors HRA Pharma
- 23 Mar 2021 Primary endpoint (Normalization of cortisol levels (urinary free cortisol)) has been met.
- 23 Mar 2021 Results presented at the 103rd Annual Meeting of the Endocrine Society.
- 24 Sep 2020 Status changed from active, no longer recruiting to completed.